Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.10.2 (
focal adhesion kinase
)
44,029
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
The
SRC
,
Abelson murine leukemia viral oncogene homolog 1
,
TEC
and C-terminal
SRC
Kinase families of non-receptor tyrosine kinases (collectively the Src module kinases) mediate an array of cellular signaling processes and are therapeutic targets in many disease states. Crystal structures of Src modules kinases provide valuable insights into the regulatory mechanisms that control activation and generate a framework from which drug discovery can advance. The conformational ensembles visited by these multidomain kinases in solution are also key features of the regulatory machinery controlling catalytic activity. Measurement of dynamic motions within kinases substantially augments information derived from crystal structures. In this review, we focus on a body of work that has transformed our understanding of non-receptor tyrosine kinase regulation from a static view to one that incorporates how fluctuations in conformational ensembles and dynamic motions influence activation status. Regulatory dynamic networks are often shared across and between kinase families while specific dynamic behavior distinguishes unique regulatory mechanisms for select kinases. Moreover, intrinsically dynamic regions of kinases likely play important regulatory roles that have only been partially explored. Since there is clear precedence that kinase inhibitors can exploit specific dynamic features, continued efforts to define conformational ensembles and dynamic allostery will be key to combating drug resistance and devising alternate treatments for kinase-associated diseases.
...
PMID:Dynamic regulatory features of the protein tyrosine kinases. 3139 55
Non-small-cell lung cancer (NSCLC) is the predominant form of lung cancer, and it is regulated by a complex signal transduction network. Single-agent targeted therapy often results in acquired resistance, which leads to treatment failure. In this study, we demonstrated that a combination of the kinase inhibitors trametinib and bosutinib can synergistically suppress the growth of NSCLC by inhibiting both the mitogen-activated protein kinase (MAPK) and
proto-oncogene tyrosine-protein kinase
(
SRC
) pathways. The combination was profiled against a panel of 22 NSCLC cell lines, including one erlotinib-resistant cell line, and this combination was found to show synergistic effects against 16 cell lines. NSCLC cell lines (HCC827, HCC827-erlotinib-resistant, and H1650) were treated with trametinib, bosutinib, or a combination of these drugs. The drug combination inhibited colony formation and induced cell apoptosis. A mechanism study showed that the phosphorylation of multiple kinases in the epidermal growth factor receptor (EGFR) signaling pathway in NSCLC was down-regulated. In addition, the combination significantly attenuated tumor growth of HCC827 xenografts with low toxicity. Our findings provide a theoretical basis for further study of the combination of MAPK and
SRC
pathway inhibitors in NSCLC, especially in the treatment of erlotinib-resistant NSCLC.
...
PMID:SRC and MEK Co-inhibition Synergistically Enhances the Anti-tumor Effect in Both Non-small-cell Lung Cancer (NSCLC) and Erlotinib-Resistant NSCLC. 3142 70
High expression of the leukemia-associated gene meningioma-1 (
MN1
) is frequently found at diagnosis of acute myeloid leukemia (AML) and associates with adverse outcomes. The presence of measurable residual disease (MRD) in complete remission (CR) indicates high risk of relapse and worse outcome in AML patients. However, the prognostic impact of
MN1
expression levels as MRD marker has not been evaluated. Digital droplet polymerase chain reaction (ddPCR) is a novel technique allowing sensitive and specific absolute gene expression quantification. We retrospectively analyzed 124 AML patients who received allogeneic hematopoietic stem cell transplantation (HSCT) in CR or CR with incomplete peripheral recovery. Absolute
MN1
copy numbers in peripheral blood were assessed prior to HSCT (median 7; range 0-29 days) using ddPCR. High pre-HSCT
MN1
/
Abelson murine leukemia viral oncogene homolog 1
gene (
ABL1
) copy numbers associated with a higher cumulative incidence of relapse after HSCT and-in relapsing patients-shorter time to relapse. In multivariable analysis, high pre-HSCT
MN1
/
ABL1
copy numbers remained an independent prognosticator for relapse after HSCT. Patients with the highest pre-HSCT
MN1
/
ABL1
copy numbers also had the highest risk of relapse.
MN1
copy number assessment also added prognostic information to nucleophosmin 1 gene (
NPM1
) mutation- and brain and acute leukemia, cytoplasmic (
BAALC
) and Wilm's tumor gene 1 (
WT1
) expression-based MRD evaluation. Our study demonstrates the feasibility of the novel ddPCR technique for
MN1
/
ABL1
copy number assessment as a marker for MRD. Evaluation of
MN1
/
ABL1
copy numbers allows the identification of patients at high risk of relapse, independently of other diagnostic risk factors and MRD markers.
...
PMID:Prognostic Impact of Blood
MN1
Copy Numbers Before Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia. 3172 6
Epigallocatechin-3-
O
-gallate (EGCG) is one of the major bioactive compounds known to be present in green tea. We previously reported that EGCG shows selective toxicity through activation of the protein kinase B (Akt)/cyclic guanosine monophosphate (cGMP)/acid sphingomyelinase (ASM) axis via targeting its receptor 67-kDa laminin receptor (67LR), which is overexpressed in cancer. However, little is known about upstream mechanisms of EGCG-elicited ASM activation. In this study we show that the
proto-oncogene tyrosine-protein kinase
Src, also known as c-src, plays a crucial role in the anticancer effect of EGCG. We showed that EGCG elicits phosphorylation of Src at Tyr 416, a crucial phosphorylation site for its activity, and that the pharmacological inhibition of Src impedes the upstream events in EGCG-induced cell death signaling including upregulation of Akt activity, increase in cGMP levels, and activation of ASM. Moreover,
focal adhesion kinase
(
FAK
), which is involved in the phosphorylation of Src, is colocalized with 67LR. EGCG treatment enhanced interaction of
FAK
and 67LR. Consistent with these findings, pharmacological inhibition of
FAK
significantly neutralized EGCG-induced upregulation of Akt activity and activation of ASM. Taken together,
FAK
/Src play crucial roles in the upstream signaling of EGCG.
...
PMID:Src Mediates Epigallocatechin-3-
O
-Gallate-Elicited Acid Sphingomyelinase Activation. 3323 40
<< Previous
1
2
3
4
5
6
7
8